ID   J82/MMC
AC   CVCL_C8D4
DR   Wikidata; Q123032760
RX   PubMed=7729958;
RX   PubMed=8077054;
CC   Population: Caucasian; Swedish.
CC   Selected for resistance to: ChEBI; CHEBI:27504; Mitomycin C (MMC; MitC).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser770Pro (c.2308T>C); ClinVar=VCV000140988; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro124Leu (c.371C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn212fs*1 (c.635_1212del578); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.2107-2A>G; ClinVar=VCV000013077; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys320Asn (c.960G>C); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0359 ! J82
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 29-06-23; Last updated: 30-01-24; Version: 2
//
RX   PubMed=7729958; DOI=10.1002/ijc.2910610326;
RA   Singh S.V., Xu B.H., Jani J.P., Emerson E.O., Backes M.G., Rihn C.,
RA   Scalamogna D., Stemmler N., Specht S., Blanock K., Katoh A., Gupta V.;
RT   "Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant
RT   human bladder cancer cell line.";
RL   Int. J. Cancer 61:431-436(1995).
//
RX   PubMed=8077054; DOI=10.1002/ijc.2910580512;
RA   Xu B.H., Gupta V., Singh S.V.;
RT   "Characterization of a human bladder cancer cell line selected for
RT   resistance to mitomycin C.";
RL   Int. J. Cancer 58:686-692(1994).
//